Synergistic effects of antiviral agents and humoral antibodies in experimental Herpesvirus hominis encephalitis.
Experimental Herpesvirus hominis encephalitis in 3-week-old Swiss mice was utilized to evaluate the antiviral effects of adenine arabinoside (ara-A), phosphonacetic acid (PAA), and humoral antibodies to H. hominis (HIG). Administration of ara-A, PAA, or HIG during the early phase of infection reduced the mortality rate of H. hominis encephalitis in mice. Combined administration of humoral antibodies with an antiviral agent (ara-A or PAA) resulted in an enhanced protection, accompanied by a decreased virus concentration in the brain tissues and a diminished tissue injury. The generality of this enhancing effect of humoral antibodies on the action of antiviral agents and its possible use in therapy of viral infections warrant further investigation.
D000818:Animals; D000914:Antibodies, Viral; D000998:Antiviral Agents / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004660:Encephalitis / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D005260:Female; D006561:Herpes Simplex / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D007136:Immunoglobulins / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010746:Phosphonoacetic Acid / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007136:Immunoglobulins; D014740:Vidarabine; D010746:Phosphonoacetic Acid